SARS-CoV-2/COVID-19: Funding Opportunities & Agency Guidance

Funding opportunities related to SARS-CoV-2/COVID-19. 

Last updated: July 27, 2020 10:30 AM.

Week of July 27 added:

GrantForward Covid-19 list of opportunities: GrantForward is providing free access to available coronavirus-related funding calls. The list is updated on a daily basis

Agency for Healthcare Research and Quality (AHRQ)

NEW AHRQ Releases Two Future Funding Opportunities for COVID-19 Responsiveness

AHRQ has released two Notices of Intent for upcoming funding opportunities designed to support studies evaluating health system and healthcare professional responsiveness to COVID-19.  The agency plans to publish notices calling for both urgent revision supplements to existing AHRQ grants, and for novel high-impact studies to be funded through the R01 mechanism.

  • Competitive revision supplements for existing AHRQ projects should “capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19.”  AHRQ expects to make at least $2.5 million available for these supplements and will release the full solicitation in April 2020.
  • For new studies related to COVID-19, AHRQ is interested in “innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic,” with a particular focus on digital health innovation and meeting the needs of vulnerable populations.  AHRQ expects to dedicate $5 million to this program. A full solicitation will be released in early May 2020, with an expected deadline in June 2020.

Air Force Office of Sponsored Programs

Guidance for Coronavirus Disease 2019 (COVID-19) No Cost Extensions (NCEs):

American Diabetes Association

The American Diabetes Association (ADA) is requesting applications (see RFA) for research focused on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications.

Recent clinical results have shown that people with diabetes are at higher risk of death from COVID-19 and that COVID-19 drives an increased risk of hyperglycemia and other complications in those with and without diabetes. This is in addition to the risk due to advanced age and chronic disease. Both the biological mechanisms underlying this risk and how to minimize it remain poorly understood. There is an urgent need for research to understand the impact of diabetes on COVID-19 and vice versa. This is true at a basic and clinical level.

The main text of the application will be a two-page application to provide all necessary study components (Aims, Significance, Preliminary data (if applicable), Research Plan, Expected Actionable Outcomes) with a one-page listing of critical references, PI Biosketch, and budget form. The goal of this RFA is to use a rapid application and review process to identify at least 10 grants of up to $100,000/each in this area and of high scientific merit for immediate funding.

The COVID-19 and Diabetes Research Awards expedited application deadline will be 5pm ET on May 22, 2020 for July 1, 2020 funding.

American Heart Association

The American Heart Association is offering fast-tracked research grants for short-term projects that can turn around results within 9-12 months to better understand the diagnosis, prevention, treatment and clinical management of COVID-19 as it relates to heart and brain health. Application and more information.

American Lung Association

New Funding Opportunity: COVID-19 and Emerging Respiratory Viruses Research Award: $100,000 per year for up to two years.

Timeline of grant process:

  • April 20, 2020: Applications accepted through proposalCentral
  • May 30, 2020: Deadline to submit an application is May 30, 2020 (11:59 PM, Eastern Time)
  • June 1-June 30, 2020: Peer Review Period
  • July 15, 2020: Outcome notifications are sent to all applicants

Contact them if you have questions. 


National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)


DOE Office of Science Memorandum to Applicants and Awardees

Health and Human Services (HHS) Office of Biomedical Advanced Research and Development Authority (BARDA)

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), issued the BAA, BAA-18-100-SOL-00003-Amendment 13, to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS BARDA has revised its Broad Agency Announcement (BAA) to only accept proposals and white papers in areas relevant to the study of COVID-19.

Areas of interest include:

  • AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
  • AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
  • AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
  • AOI 8.3 COVID-19 Vaccine
  • AOI 9.2 COVID-19 Therapeutics
  • AOI 9.3 Immunomodulators or therapeutics targeting lung repair
  • AOI 9.5 Pre-exposure and post-exposure prophylaxis
  • AOI 10 Respiratory protective devices
  • AOI 11 Ventilators
  • AOI 17 Advanced Manufacturing Technologies

Intelligence Advanced Research Projects Activity (IARPA)

IARPA Releases BAA Focused on COVID-19 Seedling Projects
The Intelligence Advanced Research Projects Activity (IARPA) has issued a broad agency announcement (BAA) soliciting proposals for unclassified seedling projects across a range of topics that are relevant to COVID-19. These include:

  • Detection and Sensing;
  • Supply Chain Management and Integrity;
  • Geo-spatial-temporal Monitoring and Mapping, with Privacy Protection;
  • Information Discovery, Information Reliability, and Collaboration Tools; and
  • Modeling, Simulation, and Predictive Analytics.

IARPA intends that projects funded under this BAA will be limited in scope and duration, with the potential to lead to longer-term efforts funded through a separate BAA in the future. The BAA explicitly calls for proposals that envision revolutionary, not evolutionary, capabilities, and that focus on research questions not currently being addressed by existing IARPA programs. In addition, IARPA will give priority to proposals that “not only provide rapid capability against the current COVID-19 pandemic, but also enhanced warning and response capacity for future similar events.”

Awards will be funded in two phases, with Phase A focusing on an initial proof of concept and Phase B being a demonstration. Individual award funding will be less than $1 million for both phases and the performance period will not exceed one year. Proposals for the initial round of selections are due July 7, 2020. The BAA will remain open through May 20, 2021 in case IARPA decides to issue additional calls. The full RFI can be found at under solicitation number “IARPA-BAA-20-01.”



NIST announces Funding Opportunity in Response to COVID-19. The National Institute of Standards and Technology announced a funding opportunity for “rapid, high-impact projects that support the nation’s response to the COVID-19 pandemic.” With funds appropriated in the CARES Act, the agency will award grants through its Manufacturing USA National Emergency Assistance Program. “Eligible institutes are invited to propose projects that may include (but are not limited to) medical or nonmedical countermeasures; grants to accelerate production of critical materials, equipment and supplies; additional production facilities; technology road-mapping for pandemic response and recovery; leveraging institute capabilities to strengthen state and community resilience; returning to the U.S. the manufacture of critical conventional drugs and ensuring supply chains for critical materials related to pandemic response; or workforce development and training for manufacturing workers.” Applications will be reviewed and considered on a rolling basis.


Office of Management and Budget (OMB)

OMB has issued a memo providing “Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19)".


Agricultural and Food Research Initiative (AFRI)

NIFA recently added a program area to its main Agricultural and Food Research Initiative RFA: Rapid Response to Novel Coronavirus (SARS-CoV-2) Impacts Across Food and Agricultural Systems.

There are four areas of priority: Health and Security of Livestock; Well-being of Farm, Food Service Providers, and Rural Americans; Economic Security; and Food Safety. Applicants should focus on critical and urgent research, extension, or integrated solutions in response to the COVID-19 pandemic and its impacts on the nation’s food and agricultural system. Applications should include strategies and knowledge that can be rapidly implemented to minimize or eliminate COVID-19 impacts on the nation’s food and agricultural system.

Deadline to submit applications is June 4. NIFA will expedite application evaluation & awards review to ensure rapid project start-up. For more information and to apply, view the RFA.